Consolidation anti-CD22 fractionated radioimmunotherapy with ⁹⁰Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial

详细信息    查看全文

• 作者：Prof Franç ; oise Kraeber-Bodere ; MD^a ; ^b ; ^&dagger ; ; ^{francoise.bodere@chu-nantes.fr} ; Amandine Pallardy ; MD^a ; ^&dagger ; ; Hervé ; Maisonneuve ; MD^c ; Loï ; c Campion ; MD^b ; Anne Moreau ; MD^a ; Isabelle Soubeyran ; MD^d ; Prof Steven Le Gouill ; MD^a ; Prof Olivier Tournilhac ; MD^e ; Etienne Daguindau ; MD^f ; Henry Jardel ; MD^g ; Nadine Morineau ; MD^h ; Krimo Bouabdallah ; MDⁱ ; Prof Emmanuel Gyan ; MD^j ; Marie-Pierre Moles ; MD^k ; Remy Gressin ; MD^l ; Prof Christian Berthou ; MD^m ; Sophie Sadot ; MD^b ; Philippe Moreau ; MDⁿ ; Bé ; né ; dicte Deau ; MD^o ; Caroline Bodet-Milin ; MD^a ; Anne-Laure Cazeau ; MD^d ; Prof Etienne Garin ; MD^p ; Prof Pierre-Yves Salaun ; MD^m ; Prof Jean-Philippe Vuillez ; MD^l ; Valé ; rie Gouilleux-Gruart ; PhD^j ; Jacques Barbet ; PhD^q ; William A Wegener ; MD^r ; Prof David M Goldenberg ; MD^r ; Prof Thierry Lamy ; MD^s ; Prof Pierre Soubeyran ; MD^d
• 刊名：The Lancet Haematology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：4
• 期：1
• 页码：e35-e45
• 全文大小：812 K
• 卷排序：4

文摘

Radioimmunotherapy represents a potential option as consolidation after chemoimmunotherapy in patients with diffuse large B-cell lymphoma who are not candidates for transplantation. We aimed to assess activity and toxicity of fractionated radioimmunotherapy using anti-CD22 90Y-epratuzumab tetraxetan as consolidation after front-line induction chemoimmunotherapy in untreated elderly patients with diffuse large B-cell lymphoma.MethodsWe did a prospective, single-group, phase 2 trial at 28 hospitals in France, with patients recruited from 17 hospitals. Eligible patients were aged 60–80 years with bulky stage 2–3 or stage 3–4 CD20-positive diffuse large B-cell lymphoma, previously untreated, and not eligible for transplantation. Patients received six cycles of R-CHOP (rituximab [375 mg/m2], cyclophosphamide [750 mg/m2], doxorubicin [50 mg/m2], and vincristine [1·4 mg/m2, up to 2 mg] all on day 1, and prednisone [40 mg/m2] daily for 5 days), administered every 14 days. 6–8 weeks after R-CHOP, responders received two doses of 15 mCi/m2 (555 MBq/m2) 90Y-epratuzumab tetraxetan administered 1 week apart. The primary endpoint was 2 year event-free survival in all registered eligible patients who received at least 1 day of study treatment; the safety analysis was done in the same population. This trial is registered with ClinicalTrials.gov, number NCT00906841.FindingsBetween Oct 22, 2008, and Dec 16, 2010, we recruited 75 patients, of whom four (5%) were excluded after central pathology review; hence, 71 (95%) patients were included in the analysis. All patients started induction treatment; 57 (80%) received radioimmunotherapy. With a median follow-up of 37 months (IQR 30–44), the estimated 2 year event-free survival was 75% (95% CI 63–84). Radioimmunotherapy toxicity consisted of grade 3–4 thrombocytopenia in 48 (84%) of 57 patients and neutropenia in 45 (79%) of 57 patients. One patient developed myelodysplastic syndrome 28 months after receiving radioimmunotherapy and one patient developed acute myeloid leukaemia 5 months after receiving radioimmunotherapy.InterpretationFractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan might be appropriate for response consolidation after induction chemotherapy in older patients with advanced diffuse large B-cell lymphoma, but further comparative studies are needed.FundingImmunomedics, Amgen, Canceropôle Grand Ouest, the GOELAMS/LYSA group and the French National Agency for Research (Investissements d'Avenir).